Kadmon shares jump on limited IPF data; Cellectis granted two US patents for editing T cells with CRISPR

Kadmon shares $KDMN spiked on some Phase II data they’re touting on on a ROCK2 inhibitor for idiopathic pulmonary fibrosis. It’s a small study and fairly hard to read without any p values, but the biotech pointed to a median decline in forced vital capacity of 48 mL at week 24, compared to a median decline of 175 mL in patients treated with best supportive care.

→ Following a European patent, Cellectis $CLLS has been granted two US patents to bolster business potential for its CAR-T treatments. The patents were issued for “the invention of certain uses of RNA-guided endonucleases” — think CRISPR/Cas9 — for the genetic engineering of T cells which are then used to fight cancer. The French biotech intends to make these patents available for licensing to companies wanting to use CRISPR tech in T cells.

Bristol-Myers Squibb $BMY is jumping on board the microbiome discovery platform at San Diego-based Sirenas. They’ll be collaborating on discovery work related to some undisclosed therapeutic targets.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->